PUVA augments cyclosporine A-mediated rat cardiac allograft survival.
PUVA, the administration of the photosensitizer 8-methoxypsoralen (8-MOP) followed by exposure of the skin to longwave ultraviolet radiation (UVA, 320-400 nm), is employed clinically for the treatment of skin diseases. PUVA is immunosuppressive and we have shown previously that it can significantly prolong skin allograft survival. This enhanced survival is associated with reduced spleen cell cytotoxic activity against donor cell targets with preserved ability of treated animals to be immunized to third-party alloantigens 5 days after exposure to a course of PUVA. To examine whether PUVA may potentiate the effect of cyclosporine A (CYA) in inhibiting cardiac allograft rejection, we employed a rat cardiac transplant model. Lewis rats (RT1(1) received cardiac allografts at a heterotopic site from Lewis Brown Norwegian (RT1(1/n)) hybrid donors. Seventy animals were equally divided into 10 groups. Starting on the day of surgery, three groups received a suboptimal doses of CYA (1.5, 4.5, or 9.0 mg/kg im), three groups received the same doses of CYA and 1.0 mg/kg of 8-MOP injected ip followed by 6.35 J/cm2 of UVA radiation to their shaved dorsums (PUVA), one group received PUVA alone, one group received UVA radiation alone, one group received 8-MOP alone, and the final group received no treatment. Therapy was carried out daily for 7 days and survival of the allograft was assessed by daily palpation of the transplanted heart.(ABSTRACT TRUNCATED AT 250 WORDS)
Horvath
K A
KA
Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts 02115.
Granstein
R D
RD
D000818:Animals; D016572:Cyclosporine / Q000494:pharmacology*; D005260:Female; D006085:Graft Survival / Q000187:drug effects*; D016027:Heart Transplantation; D007958:Leukocyte Count; D011701:PUVA Therapy; D051381:Rats; D011919:Rats, Inbred Strains; D014184:Transplantation, Homologous
D016572:Cyclosporine